Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 8/20 | 0.62 |
| ▸ | CYP11B2 | P19099 | 8/20 | 0.62 |
| ▸ | TNF | P01375 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | PRKCI | P41743 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2082545 | 0.83 | TDP1 (0.66) | CYP11B1CYP11B2TNFTDP1HTT | |
| SCHEMBL15552137 | 0.82 | CYP11B1 (0.57) | CYP11B1CYP11B2TNFTDP1HTT | |
| SCHEMBL2542851 | 0.79 | PRKCI (0.52) | CYP11B1CYP11B2TNFHTTSMN1; SMN2 | |
| SCHEMBL13907295 | 0.78 | CYP11B1 (0.89) | CYP11B1CYP11B2TNFTDP1HTT | |
| SCHEMBL30826274 | 0.78 | CYP11B1 (0.77) | CYP11B1CYP11B2TNFTDP1HTT | |
| SCHEMBL4142913 | 0.78 | CYP11B1 (0.77) | CYP11B1CYP11B2TNFTDP1HTT | |
| SCHEMBL30497324 | 0.77 | FGFR1 (0.54) | MEN1KMT2APRKCI | |
| SCHEMBL230002 | 0.77 | CYP11B1 (1.00) | CYP11B1CYP11B2TNFTDP1HTT | |
| SCHEMBL31357411 | 0.77 | CYP11B1 (1.00) | CYP11B1CYP11B2TNFTDP1HTT | |
| Bromide SCHEMBL31253900 | 0.77 | CYP11B1 (0.75) | CYP11B1CYP11B2TNFTDP1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102442952-A | Cyclic N-heterocyclic carbene metal complex, and preparation method and application thereof | UNIV TIANJIN NORMAL | 2012-05-09 | — | — | CN | claimed |
| CN-102321104-A | Alkyl-bridged N-heterocyclic dicarbene metal complex as well as preparation method and application thereof | UNIV TIANJIN NORMAL | 2012-01-18 | — | — | CN | claimed |
| CN-108947963-B | Benzimidazole hexafluorophosphate compound and preparation method and application thereof | 天津师范大学 | 2020-11-10 | — | — | CN | disclosed |
| CN-104860966-B | Tetradentate nitrogen-heterocyclic Carbene silver complex and preparation method and application thereof | 天津师范大学 | 2017-01-11 | — | — | CN | disclosed |
| CN-102321104-A | Alkyl-bridged N-heterocyclic dicarbene metal complex as well as preparation method and application thereof | UNIV TIANJIN NORMAL | 2012-01-18 | — | — | CN | disclosed |
| US-7528251-B2 | Method for enantioselective preparation of sulphoxide derivatives | SIDEM PHARMA SA (LU) | 2009-05-05 | — | — | US | disclosed |
| EP-1802620-B1 | METHOD FOR ENANTIOSELECTIVE PREPARATION OF SULPHOXIDE DERIVATIVES | SIDEM PHARMA S A (LU) | 2008-12-17 | — | — | EP | disclosed |
| US-20070299261-A1 | Method For Enantioselective Preparation Of Sulphoxide Derivatives | SIDEM PHARMA SA (LU) | 2007-12-27 | — | — | US | disclosed |
| EP-1802620-A1 | METHOD FOR ENANTIOSELECTIVE PREPARATION OF SULPHOXIDE DERIVATIVES | Sidem Pharma (LU) | 2007-07-04 | — | — | EP | disclosed |
| EP-1740571-A1 | A PROCESS FOR PREPARING PYRIDINYLMETHYL-1H- BENZIMIDAZOLE COMPOUNDS IN ENANTIOMERICALLY ENRICHED FORM OR AS SINGLE ENANTIOMERS | Hetero Drugs Limited (IN) | 2007-01-10 | — | — | EP | disclosed |
| WO-2006037894-A1 | METHOD FOR ENANTIOSELECTIVE PREPARATION OF SULPHOXIDE DERIVATIVES | SIDEM PHARMA S.A. (LU) | 2006-04-13 | — | — | WO | disclosed |
| WO-2005105786-A1 | A PROCESS FOR PREPARING PYRIDINYLMETHYL-1H- BENZIMIDAZOLE COMPOUNDS IN ENANTIOMERICALLY ENRICHED FORM OR AS SINGLE ENANTIOMERS | HETERO DRUGS LIMITED (IN) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299261-A1 | Method For Enantioselective Preparation Of Sulphoxide Derivatives | TST, ADH1A, ADH1C | CYP11B1 75/4885CYP11B2 94/4885TNF 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.